Pitolisant
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Sep 20, 2022 → May 1, 2023
NCT ID
NCT05581576About Pitolisant
Pitolisant is a approved stage product being developed by Harmony Biosciences for Restless Legs Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT05581576. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03433131 | Pre-clinical | Completed |
| NCT07219485 | Phase 3 | Recruiting |
| NCT05581576 | Approved | UNKNOWN |
| NCT05458128 | Phase 3 | Completed |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| ASP8825 | Astellas Pharma | Phase 3 | 77 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Apomorphine Sublingual Film + Placebo | Sumitomo Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| pregabalin + placebo + pramipexole | Pfizer | Phase 3 | 76 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| cabergoline + levodopa | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Levetiracetam (Keppra) | UCB | Phase 2 | 49 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |